MedTrace Logo

DPP-4 Inhibition and TZD for DM Prevention

NCT01006018 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2013-12-05

Study results available
· View outcomes & findings →

Summary

To determine whether treatment with the diabetes medication, Januvia (sitagliptin), with or without another diabetes medicine, Actos (pioglitazone), will improve insulin secretion and insulin response individuals with Impaired Glucose Tolerance (IGT), a form of prediabetes.

Conditions

  • Prediabetic State

Interventions

DRUG

Sitagliptin + Pioglitazone PLACEBO

Sitagliptin 100 mg tablet daily + Pioglitazone PLACEBO 15 mg capsule daily

DRUG

Sitagliptin + Pioglitazone

Sitagliptin 100 mg tablet daily + Pioglitazone 15 mg capsule daily

DRUG

PLACEBO

Sitagliptin placebo 100 mg tablet daily + Pioglitazone placebo 15 mg capsule daily

Sponsors & Collaborators

Principal Investigators

  • Mary Rhee, MD · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01006018 on ClinicalTrials.gov